Lipid management in high risk coronary patients: how effective are we at secondary intervention?

Ying Yan Zhu1, Philip A R Hayward, David L Hare

  • 1The University of Melbourne, Swanston St Parkville VIC, Melbourne Medical School, Australia. yingyan.zhu@gmail.com

Heart, Lung & Circulation
|December 14, 2011
PubMed

Insights

Long-term follow-up after coronary bypass surgery (CABG) shows improved lipid levels, but most patients still don't meet national targets, except for HDL-C. Careful monitoring is key for cardiovascular health post-CABG.

Area of Science:

  • Cardiovascular medicine
  • Lipidology
  • Clinical outcomes research

Background:

  • Coronary bypass surgery (CABG) is a vital intervention for cardiovascular disease.
  • Optimizing lipid levels post-CABG is crucial for long-term patient outcomes and preventing recurrent events.
  • Current guidelines set specific lipid targets (total cholesterol, LDL-C, HDL-C, triglycerides) for cardiovascular risk reduction.

Purpose of the Study:

  • To determine the proportion of patients achieving and sustaining target lipid levels after CABG.
  • To evaluate lipid level attainment during long-term follow-up (up to 13 years) post-CABG.
  • To compare lipid control pre-operatively, during follow-up, and at the most recent assessment.

Main Methods:

  • Analysis of a prospectively compiled database of 440 patients undergoing CABG.
  • Collection and analysis of 6077 lipid assays (total cholesterol, LDL-C, HDL-C, triglycerides) over up to 13 years.
  • Calculation of annualised mean lipid exposure and comparison with National Heart Foundation guidelines.

Main Results:

  • Pre-operative target attainment was low: 16% (total cholesterol), 14% (LDL-C), 39% (triglycerides), with 64% for HDL-C.
  • Long-term follow-up showed improved but suboptimal attainment: 24% (total cholesterol), 20% (LDL-C), 53% (triglycerides), 83% (HDL-C).
  • The most recent review indicated significant improvements: 47% (total cholesterol), 43% (LDL-C), 62% (triglycerides), 68% (HDL-C).

Conclusions:

  • Despite improvements with careful follow-up, only HDL-C targets are consistently met by most CABG patients.
  • Over half of patients fail to achieve national non-HDL lipid targets post-CABG.
  • Enhanced lipid management strategies may be necessary to improve outcomes for CABG patients.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...